HC Wainwright restated their buy rating on shares of Advaxis (NASDAQ:ADXS) in a research note released on Wednesday morning, The Fly reports.

Separately, Jefferies Financial Group downgraded Advaxis from a buy rating to a hold rating and reduced their price target for the stock from $9.00 to $2.00 in a research report on Wednesday, June 13th.

Shares of ADXS stock opened at $0.81 on Wednesday. Advaxis has a 12-month low of $0.77 and a 12-month high of $5.20.

In other Advaxis news, Director Roni Appel purchased 33,333 shares of Advaxis stock in a transaction dated Tuesday, September 11th. The shares were acquired at an average cost of $1.20 per share, with a total value of $39,999.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.21% of the company’s stock.

Several hedge funds have recently modified their holdings of ADXS. BlackRock Inc. increased its position in shares of Advaxis by 28.2% during the first quarter. BlackRock Inc. now owns 2,925,417 shares of the biotechnology company’s stock worth $4,943,000 after purchasing an additional 644,201 shares in the last quarter. DAFNA Capital Management LLC increased its position in shares of Advaxis by 182.2% during the first quarter. DAFNA Capital Management LLC now owns 697,000 shares of the biotechnology company’s stock worth $1,178,000 after purchasing an additional 450,000 shares in the last quarter. Franklin Street Advisors Inc. NC acquired a new position in shares of Advaxis during the second quarter worth $190,000. LMR Partners LLP acquired a new position in shares of Advaxis during the second quarter worth $171,000. Finally, Paloma Partners Management Co acquired a new position in shares of Advaxis during the second quarter worth $265,000. 21.55% of the stock is currently owned by institutional investors and hedge funds.

Advaxis Company Profile

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Featured Story: Penny Stocks, Risk and Reward Factors

The Fly

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.